USD10
CLYM Shares
About Climb BioClimb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
USD10
CLYM Shares
About Climb BioClimb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$727.24M
OPEN PRICE
$12.20
LOW (1Y)
$1.36
HIGH (1Y)
$14.42
LOW (24H)
$12.14
HIGH (24H)
$13.53
VOLUME (24H)
$1.37M
8.85%
Price history
Time | Price | Change |
|---|---|---|
Today | $12.20 | |
1 Day | $12.15 | |
1 Week | $14.10 | |
1 Month | $11.82 | |
1 Year | $1.41 |
Past performance is not a reliable indicator of future results.
Discover more
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.